Leuprorelin
Leuprorelin is a pharmaceutical drug with 24 clinical trials. Currently 6 active trials ongoing. Historical success rate of 85.7%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
6
Mid Stage
12
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.7%
12 of 14 finished
14.3%
2 ended early
6
trials recruiting
24
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect
COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
Clinical Trials (24)
Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect
COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Detect V / CHEVENDO (Chemo vs. Endo)
A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 24